search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (36)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (15)
- General Venture Capital (46)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (67)
monthly archive
- December 2024 (1)
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Category Archives: Bioentrepreneurship
Keeping It Simple: What Really Matters For Emerging Enterprises
September 4, 2024
By Ankit Mahadevia, chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC A common theme in startup literature is that by cutting a range of unnecessary tasks, a step-change in results will follow. I’ve found
A Biotech Midsummer’s Madness
August 21, 2024
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Greetings from Lake Winnipesaukee in NH where I am at this time every year. It’s midsummer and vacation time for me and the
A Molecular Biologist’s Advice For Life
July 1, 2024
Having just turned 50, I’ve been reflecting on my first half-century of late… many fun and impactful moments, a few regrets, and a life I’ve tried to live to the fullest. One thread that has run throughout it has been
Every Second Counts
March 11, 2024
By Aoife Brennan, former CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I have recently completed a turn around the biotech sun: a seven-year assignment at Synlogic that ended this year when an early readout
The Long and Winding (Biotech) Road…
January 25, 2024
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC Well, this is a first…. while I have read and enjoyed the the LifeSci VC blog for years, being asked to contribute for
Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market
November 28, 2023
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. @JebKeiper Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired by Takeda for $4 billion upfront. To
Growth Mindset for the “Crystallized Intellect”
August 30, 2023
More Musings from an Old CEO By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC The only way we grow as leaders is by stretching the limits of who we are
Playing Small Ball
November 1, 2022
By Robert Clarke, CEO and founder of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has been a hallmark year for Kinaset Therapeutics as we’ve continued to advance our P1b trial with our lead asset.
Breaking Up Is Hard To Do – But It Doesn’t Have To Be!
October 4, 2022
By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC As one thinks about the iconic break-up lines, it doesn’t take long to come up with: It’s not you; it’s me… I am
A Virtual Company In A Virtual World
March 16, 2022
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC. In December 2019, I was in London meeting with my future co-founders to discuss an asset that would eventually become the cornerstone of
Heads Up And Eyes Wide Open
February 7, 2022
By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches features of LifeSciVC When your team’s priority is to execute a well-formed plan, then a “heads down” focus is critical. We all recognize this situation, using
Reimagining The Workplace Post Pandemic
April 15, 2021
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace. CEO’s that I have spoken
Leave a Ladder Down, Part Deux
July 20, 2020
By Samantha Truex, CEO of QuenchBio, as part of the From The Trenches feature of LifeSciVC I have been privileged to read and write for this LifeSciVC blog for a handful of years now. One of my favorite editions is
Navigating The Unknown: Practical Thoughts On A Team That Can Rise To The Occasion
September 5, 2019
This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. One of the joys of building a company is that meeting one’s milestones routinely places us in positions that
Biotech Startups And The Hard Truth Of Innovation
May 20, 2019
Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative startups aren’t just about being cool and nimble, having beer taps in the kitchen, or an
All A-Board
February 14, 2019
This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC. In a 2014 analysis of biotech boards and a reprise analysis in 2016, Bruce Booth
Science2Startup 2019: Bringing Venture & Academia Together
October 15, 2018
After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. Working with a steering committee comprised of Atlas,
Float Like A Butterfly: Agility In Biotech
June 13, 2018
This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC. In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around
Grey Hair In the C-Suite: Experience, Age, And IPOs In Biotech
February 26, 2018
Biotech venture investors often prefer to back executives and entrepreneurs with a bit of grey hair. Seasoned industry veterans that possess leadership charisma along with years of experience, and the oft-accompanying learned judgement, are highly sought-after in biopharma’s seemingly endless
Painful Truth: Successful Failure Of A Biotech Startup
November 17, 2017
Back in the summer, I got the call that no biotech venture investor wants to get. On the morning of August 8th, I received an urgent text of “can you talk now?” quickly followed with a call. I learned then
Launching Science2Startup: Connecting Academics With Venture
October 6, 2017
We’re excited to announce the launch of Science2Startup, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. This event is in many ways a relaunch of the successful URES (University Research
Distinctive Biotech Corporate Culture: Walk The Talk
July 25, 2017
Corporate culture is often hard to precisely define. Yet it’s always cited as being one of the key drivers of company outperformance, especially for startups. Recently I was asked to define what culture means by a young entrepreneur: beyond the
The Inescapable Gravity Of Biotech’s Key Clusters: The Great Consolidation Of Talent, Capital, & Returns
March 21, 2017
Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these
Our Experience With First-Time Biotech CEOs: Five Behaviors That Matter
May 25, 2016
Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,
Moving From Academia To Successful Biotech: Optimizing Tech Transfer
April 26, 2016
University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating – and optimizing – this tech transfer process is therefore critical to the
Entrepreneuring Post-Pharma
March 1, 2016
This blog was written by Jason Gardner, Atlas EIR and founding CEO of a new stealth-stage startup, as part of the From The Trenches feature of LifeSciVC. What are you doing? This is the most frequent yet simple question that
Top Ten Most Engaging LifeSciVC Posts Of 2015
December 28, 2015
As 2015 comes to a conclusion, it’s a good time reflect on the year’s progress – celebrating the wins, thinking through the losses, and learning from both. One specific reflection of late regards this blog: I’ve looked back at the
Biotech New Venture Formation: Reflecting On A Decade’s Changing Dynamics
December 18, 2015
This year I celebrated my 10-year work anniversary with Atlas. Hard to believe how fast a decade flies by, and this milestone triggered some reflections on how times have changed in biotech and the early stage venture business. As we
A Leadership Imperative: Getting More C-Level Women In Biotech
September 28, 2015
The relative absence of women from significant leadership roles in the biotech industry has rightfully become a front-and-center topic, in part prompted by a wave of coverage on the subject (here, here, here, here). Liftstream’s recent report, titled “Diversifying the
Biotech Circa 2015 AD: Where Are The Women?
September 28, 2015
This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. A few weeks ago, a member of our board sent an email to a group of biotech CSOs suggesting that
Autonomy, Ownership, And Trust – Keys To Entrepreneurial Success
August 12, 2015
This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. I had an interesting discussion with a veteran of a rapidly growing biotech. He’d been at his company at the
The Other Side Of The Fence
August 5, 2015
This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In a previous post I was extolling the virtues of leading a private company. Specifically, the freedom of being able
Finding Success In Failing Early: All About Execution
March 18, 2015
In a period of surging optimism for our industry, it’s easy to forget that historically most of the therapeutic projects we undertake don’t make it to the market (see the data here if you absolutely have to remind yourself of
Biotech CEOs: Observations In Thermodynamics And Kinetics
March 16, 2015
A great CEO makes all the difference, and a poor one destroys a ton of value. But recruiting great CEOs is often hard, especially when picking, as is most often the case, from a list of potential first-time CEOs. How
Public Pool Or Private Beach
February 23, 2015
Three years ago, I was walking across One Kendall Square in pursuit of a late lunch and bumped into a friend – another biotech CEO. I was a year into my role as CEO of Idenix, a publicly traded biotech
Learnings From a Reluctant Entrepreneur
February 11, 2015
I am a scientist by vocation and training and an entrepreneur by accident. I got into the business of starting companies when I decided almost a decade ago that I wanted to work on a new crazy therapeutic modality and the